M. Lazenby

Most-cited papers

1. Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.

   F. Ostronoff, M. Othus, M. Lazenby, E. Estey +15 more

   2015Journal of Clinical Oncology139 citations Open access

   Semantic Scholar

   Save

2. The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial

   M. Lazenby, A. Gilkes, C. Marrin, Anna Evans +2 more

   2014Leukemia62 citations Open access

   Semantic Scholar

   Save

3. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine

   Elisabeth Walsby, M. Lazenby, Chris Pepper, A. Burnett

   2011Leukemia45 citations Open access

   Semantic Scholar

   Save

4. Synthesis and preliminary evaluation of poly(amidoamine)-melittin conjugates as endosomolytic polymers and/or potential anticancer therapeutics.

   Nathalie Lavignac, M. Lazenby, J. Franchini, P. Ferruti +1 more

   2005International journal of pharmaceutics45 citations Open access

   Semantic Scholar

   Save

5. The HSP90 inhibitor NVP‐AUY922‐AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells

   Elisabeth Jane Walsby, M. Lazenby, Chris Pepper, S. Knapper +1 more

   2013British Journal of Haematology33 citations

   Semantic Scholar

   Save

6. Synthesis and endosomolytic properties of poly(amidoamine) block copolymers.

   Nathalie Lavignac, M. Lazenby, P. Foka, B. Malgesini +3 more

   2004Macromolecular Bioscience31 citations Open access

   Semantic Scholar

   Save

7. The ATRA Question In AML: Lack Of Benefit Overall Or In Any Molecular Subgroup In The NCRI AML16 Trial

   A. Burnett, R. Hills, L. Friis, L. Kjeldsen +6 more

   20135 citations

   Semantic Scholar

   Save

8. The Impact of FLT3-ITD and NPM1 Mutational Status on the Outcome of ATRA Therapy in Patients with Non-APL AML: Results of the UK MRC AML12 Trial

   R. Gale, R. Hills, Claire L. Green, Yashma Patel +5 more

   20084 citations

   Semantic Scholar

   Save

9. Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3‐ITD acute myeloid leukaemia

   J. Zabkiewicz, M. Lazenby, G. Edwards, C. Bygrave +7 more

   2020British Journal of Haematology3 citations Open access

   Semantic Scholar

   Save

10. Extracellular Microvesicle Cytokines Secreted from Bone Marrow Mesenchymal Cells Mediate Proliferative and Survival Advantage in Acute Myeloid Leukaemia

    M. Lazenby, O. Ottmann, K. WIlson, Caroline Alvares +1 more

    2018Blood2 citations Open access

    Semantic Scholar

    Save

11. Characterisation of extracellular vesicles from the microenvironment in high risk acute myeloid leukaemia

    M. Lazenby

    20190 citations

    Semantic Scholar

    Save

12. Azacytidine as a Maintenance Therapy in Elderly AML Progressively Demethylates CpG Sites within the p16 Gene

    M. Dellett, M. Lazenby, A. Burnett, K. Mills

    20080 citations

    Semantic Scholar

    Save

13. Specific and global methylation status in elderly AML and high risk MDS patients

    M. Dellett, Eleanor L. Woodward, M. Lazenby, H. Coyler +2 more

    20080 citations

    Semantic Scholar

    Save